
Home » Pipeline
Pipeline
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Compass Therapeutics | CTX-471 | metastatic or locally advanced solid cancers | Phase 1 trial initiated |
Cyxone | T20K | multiple sclerosis (MS) | Phase 1 trial initiated |
SOTIO | SO-C101 | advanced/metastatic solid tumors | Phase 1/1b trial initiated |
TARIS Bio | TAR-200 in combination with Opdivo (nivolumab) | muscle-invasive bladder cancer (MIBC) | Phase 1b trial initiated enrolling 25 subjects with MIBC who are scheduled for radical cystectomy |
Metacrine, Inc. | MET409 | non-alcoholic steatohepatitis (NASH) | Phase 1b trial initiated |
IDEAYA Biosciences, Inc.o | IDE196 | solid tumors that harbor GNAQ/11 mutations or PRKC fusions | Phase 1/2 trial initiated |
Trovagene, Inc. | onvansertib in combination with FOLFIRI and Avastin (bevacizumab) | metastatic colorectal cancer (mCRC) with a KRAS mutation (NCT03829410) | Phase 1b/2 trial initiated |
EIP Pharma, Inc. | neflamapimod | Huntington's disease | Phase 2 trial initiated enrolling 16 subjects at a site in Cambridge UK |
Cara Therapeutics, Inc. | Oral KORSUVA (CR845/difelikefalin) | pruritus in subjects with atopic dermatitis (AD) | Phase 2 trial initiated enrolling 240 adult subjects with AD |
Dilafor AB | tafoxiparin | pregnant women planned for labor induction | Phase 2b trial initiated |
NeuroRx, Inc. | NRX-101 | Severe Bipolar Depression and Acute Suicidal Ideation and Behavior (ASIB) | Phase 2b/3 trial initiated enrolling 140 subjects with Severe Bipolar Depression and ASIB who are stabilized following a single IV infusion of ketamine JPS Health Network in Fort Worth, Texas |
Mirum Pharmaceuticals | maralixibat | progressive familial intrahepatic cholestasis (PFIC) in pediatric subjects | Phase 3 trial initiated enrolling 30 subjects with residual BSEP function (PFIC2 non-truncating) aged one to 17 years |
CStone Pharmaceuticals | avapritinib | gastrointestinal stromal tumors (GIST) | Phase 3 trial initiated |
Sensorion | SENS-401 | Sudden Sensorineural Hearing Loss (or SSNHL) | IND approval granted by the FDA |
Karyopharm Therapeutics | selinexor in combination with dexamethasone | relapsed refractory multiple myeloma in subjects who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody | Approval granted by the FDA |
ConTIPI Medical, Ltd. | ProVate | pelvic prolapse in women | Approval granted by the FDA |
Azurity Pharmaceuticals | Katerzia (amlodipine) Oral Suspension, 1 mg/mL | hypertension (high blood pressure) in adults and pediatric patients six years of age and older and coronary artery disease in adults | Approval granted by the FDA |
Upcoming Events
-
05Dec
-
14Apr